Allarity Therapeutics
- Country
- 🇺🇸United States
- Ownership
- Public
- Employees
- 6
- Market Cap
- -
- Website
- http://www.allarity.com
- Introduction
Allarity Therapeutics, Inc. engages in the development of drugs for personalized treatment of cancer guided by its proprietary Drug Response Predictor (DRP) technology. The company operates in two geographic areas: Denmark and the United States. The company was founded on April 4, 2021 and is headquartered in Boston, MA.
Clinical Trials
9
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (8 trials with phase data)• Click on a phase to view related trials
Study to Determine the Maximum Tolerated Dose (MTD) of PARPi 2X-121 Monotherapy and the MTD of Dovitinib in Combination With 2X-121 in Patients With Advanced Solid Tumors
- First Posted Date
- 2022-10-07
- Last Posted Date
- 2025-05-07
- Lead Sponsor
- Allarity Therapeutics
- Target Recruit Count
- 40
- Registration Number
- NCT05571969
- Locations
- 🇺🇸
Carolina BioOncology, Huntersville, North Carolina, United States
🇺🇸University Hospitals Cleveland Medical Center, Cleveland,, Ohio, United States
Anti-tumor Effect of Ixabepilone in Metastatic Breast Cancer (mBC) Selected by the Ixabepilone DRP.
- First Posted Date
- 2021-03-12
- Last Posted Date
- 2025-02-04
- Lead Sponsor
- Allarity Therapeutics
- Target Recruit Count
- 60
- Registration Number
- NCT04796324
- Locations
- 🇧🇪
Antwerp University Hospital, Antwerp, Edegem, Belgium
🇧🇪Onze-Lieve-Vrouwziekenhuis, Aalst, Belgium
🇧🇪Clin. Univ. Saint-Luc, Brussels, Belgium
Investigation of the Anti-tumor Effect of 2X-121 in Patients With Recurrent, Advanced Ovarian Cancer
- First Posted Date
- 2019-03-18
- Last Posted Date
- 2025-05-08
- Lead Sponsor
- Allarity Therapeutics
- Target Recruit Count
- 40
- Registration Number
- NCT03878849
- Locations
- 🇺🇸
OU Health Stephenson Cancer, Oklahoma City, Oklahoma, United States
🇺🇸Swedish Center for Research and Innovation, Seattle, Washington, United States
Clinical Pre-screening Protocol for Ovarian Cancer
- Conditions
- Ovarian Cancer
- First Posted Date
- 2019-03-18
- Last Posted Date
- 2025-01-23
- Lead Sponsor
- Allarity Therapeutics
- Target Recruit Count
- 60
- Registration Number
- NCT03877796
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸OU Health Stephenson Cancer Center, Oklahoma City, Oklahoma, United States
🇺🇸Swedish Center for Research and Innovation, Seattle, Washington, United States
Irofulven in AR-targeted and Docetaxel-Pretreated mCRPC Patients With Drug Response Predictor (DRP®)
- Conditions
- Metastatic Castration-Resistant Prostate Cancer Patients
- Interventions
- Combination Product: Prednisolone 10 mg
- First Posted Date
- 2018-08-22
- Last Posted Date
- 2025-01-23
- Lead Sponsor
- Allarity Therapeutics
- Target Recruit Count
- 15
- Registration Number
- NCT03643107
- Locations
- 🇩🇰
Rigshospitalet, Dept. Of Oncology, Copenhagen, Denmark
- Prev
- 1
- 2
- Next
News
Allarity Therapeutics Unveils Novel Predictive Tool for Daratumumab Response in Multiple Myeloma Patients
• Allarity Therapeutics has developed a new Drug Response Predictor (DRP®) for daratumumab that can identify multiple myeloma patients most likely to benefit from treatment, as presented at AACR 2025. • The daratumumab DRP® is based on 53 genes associated with treatment sensitivity or resistance, and has demonstrated ability to predict treatment outcomes and survival in clinical samples. • This marks Allarity's first DRP® for an antibody therapy, expanding beyond small-molecule drugs and positioning the company for potential strategic partnerships in precision oncology.
Allarity Therapeutics Advances Stenoparib for Ovarian Cancer with Phase 2 Trial Expansion
Allarity Therapeutics is expanding its Phase 2 clinical trial of stenoparib for advanced ovarian cancer, aiming to optimize dosing and patient selection.
Allarity Therapeutics' Stenoparib Shows Promise in Advanced Ovarian Cancer Phase 2 Trial
Allarity Therapeutics reports that two patients with advanced ovarian cancer have remained on stenoparib treatment for over 14 months in a Phase 2 trial.